Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne m…
Author: GlobeNewswire
MDxHealth Reports Financial Year 2020 Results and Provides Outlook for 2021
NEWS RELEASE – REGULATED INFORMATION 3 MARCH 2021, 07:00 A.M. CET Conference call with Q&A today at 08:00 CET / 07:00 GMT, details provided below IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2021 – MDxHealth SA (Euronext: MDXH.BR), a commercia…
Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia
• The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable safety…
ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will p…
In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit
In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit. The consolidated, preliminary financial data…
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an u…
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) — Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of …
Rezolute to Participate in Upcoming Investor Conferences in March
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company’s CEO and Founder, will be presenting at the following upcoming investor conferences: Cowen 41st Annual Heal…
Pacific Biosciences Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today an…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 1, 2021, the compensation committee of BridgeBio’s boar…